Vaccination to improve the persistence of CD19 CAR T cells in relapsed ALL

Bookmark and Share
Published: 23 Sep 2016
Views: 2244
Dr Sara Ghorashian - University College London, London, UK

Dr Ghorashian speaks with ecancertv at Childhood Cancer 2016 about results from a European trial of CD19 CAR T cells to treat relapsed ALL.

She describes the creation, transduction and activation of the T cell line, and that vaccination of patients did result in short term benefit.

Dr Ghorashian considers that broader impact of engineered T cells, and looks forward to a second generation of CAR cells for her further research.